Mersana Therapeutics has teed up its first clinical program for the lead antibody drug conjugate in its pipeline, gaining $33 million in a new round to fund the work.
Four months after restructuring the ailing Aegerion ($AEGR) and axing about 80 staffers, CEO Mary Szela has completed the deal she wanted to bring in a late-stage asset.
Sofinnova Partners' Antoine Papiernek not only agreed to co-lead the $33 million B round, he grabbed a seat on the board along with Nilesh Kumar from co-lead investor Novo A/S.
Three years after it was forced to restructure the company in the wake of the failure of its then lead drug, Infinity Pharmaceuticals ($INFI) finds itself in a new crisis.
Gilde Healthcare has put together its fourth healthcare fund, looking to back a range of biotechs, device companies and digital health with a fresh injection of $285 million.